CN1764471A - 趋化因子受体激动剂用于干细胞移植的用途 - Google Patents
趋化因子受体激动剂用于干细胞移植的用途 Download PDFInfo
- Publication number
- CN1764471A CN1764471A CNA2004800079361A CN200480007936A CN1764471A CN 1764471 A CN1764471 A CN 1764471A CN A2004800079361 A CNA2004800079361 A CN A2004800079361A CN 200480007936 A CN200480007936 A CN 200480007936A CN 1764471 A CN1764471 A CN 1764471A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- receptor
- cell
- cfu
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
Abstract
一种药物,其包含受体的至少一种激动剂或其组合以及药学上可接受的载体,其中所述受体选自CCR3、CCR6或CCR8受体。
Description
本发明涉及包含受体的至少一种激动剂的药物、药剂用于制备促进干细胞归巢的药物中的用途以及促进造血干细胞成功归巢的方法。
概述
发现趋化因子受体CCR3、CCR6和CCR8的趋化因子受体激动剂能增加造血干细胞和祖细胞对SDF-1α信号的敏感性。发现CCR3、CCR6和CCR8激动剂能促进干细胞移植过程中干细胞向骨髓的归巢。
发明领域
本发明涉及使用趋化因子受体CCR3、CCR6和CCR8的趋化因子受体激动剂促进干细胞移植过程中干细胞向骨髓归巢的方法。
背景技术
造血干细胞是能够自我复制、维持再生细胞的连续来源并分化、产生血细胞谱系各种形态上可识别前体的非常原始的血细胞祖先。这些前体是不能自我复制且必须分化为成熟血细胞的非成熟血细胞。在骨髓微环境中,干细胞在整个生命过程中自我复制并活跃地维持所有成熟血细胞谱系的连续产生。
骨髓移植正日益作为对日益增多的疾病的有效疗法用于人类,所述的疾病包括癌症如白血病、淋巴瘤、骨髓瘤和选定的实体瘤以及非恶化疾病如再生障碍性贫血、免疫缺陷和先天性代谢错误。骨髓移植的目的是为宿主提供将分化为成熟血细胞的健康干细胞群,替代缺陷的或致病性的细胞谱系。
用于移植的骨髓来源可以是自体的、同基因的或异基因的。优选的是自体的骨髓或来自HLA匹配同胞的骨髓,来自HLA不匹配供体的骨髓也可用于移植。
骨髓移植中的复杂因素包括移植物排斥和移植物-宿主疾病(GVHD)。由于供体T淋巴细胞发现能导致动物体内的GVHD,预防或缓解GVHD的一种方法包括在移植之前从供体骨髓中除去T细胞。这可以通过不同的技术实现。除去T细胞的骨髓的广泛使用有效预防GVHD,但是不幸地导致移植物排斥(HLA匹配的接受者中为10-15%,HLA非匹配的接受者中为50%)和移植物无功能(高达50%)的高发率。
骨髓移植中的另一个问题是即使不发生移植物排斥或GVHD也难以实现长期成功的移入。目前,成功移植的患者与健康个体相比具有非常低水平的干细胞和产生成熟血细胞的非成熟祖细胞。
干细胞从功能上说具有归巢到骨髓并使移植的接受者持久聚集骨髓样和淋巴样细胞的能力。介导人干细胞向骨髓归巢并移入的过程涉及细胞因子、趋化因子和粘附分子的复杂相互作用。
我们对造血系统调控和层级结构的多数认识来源于小鼠中的研究,其中在长期重构分析中鉴别并定量干细胞。相比之下,我们对人造血生物学的认识是有限的,这是因为大多基于分析和定量重聚集的干细胞。
正在进行深入研究以理解介导人干细胞向骨髓的归巢和移入的过程。最近,几个研究组已经建立了人类干细胞移植的体内模型,例如将其植入免疫缺陷小鼠,如辐射beige小鼠、裸鼠、Xid(X连锁免疫缺陷)小鼠、SCID和非肥胖性糖尿病SCID(NOD/SCID)小鼠,和宫内植入绵阳胚胎,从而成功实现髓样细胞和淋巴样细胞共同的多谱系移植。
之前,基于原初人SCID重聚集细胞(SRC)可以在经静脉移植的SCID或NOD/SCID小鼠的骨髓中持续重建高水平髓样细胞和淋巴样细胞群的能力,发明人建立了功能性体内分析原始的人SCID重聚集细胞的方法([1、2])。动力学实验表明只有小部分的移植细胞移入,这些细胞通过广泛地增殖和分化重聚集于小鼠骨髓。另外,原始人细胞还保留移入二级鼠接受者的能力[3]。富含CD34和CD38细胞表面抗原表达的群体的移植表明SRC的表型为CD34+CD38-[2]。由于最近的研究表明非成熟的人CD34-细胞和更为分化的CD34+CD38+细胞具有有限的移入潜力,还可能存在其他的重聚集细胞[4、5]。
越来越多的证据表明干细胞向骨髓归巢是多步骤过程。造血干细胞迁移(trafficking)中涉及的机制长期以来都不清楚。
在过去几年里,已经认识到了特定分泌的(如细胞因子)和细胞结合的蛋白质(如粘附分子)在祖细胞迁移和归巢中的作用[6-9]。更近期,研究表明细胞因子可以在祖细胞迁移、尤其是干细胞向骨髓(BM)的归巢中发挥重要作用[9-12]。有意思的是,炎症期间成熟白细胞的外渗和未成熟祖细胞和干细胞向脊髓归巢可能至少部分依赖于类似的机制[8]。炎性组织和造血微环境具有类似性,如在微血管内皮上表达特定的粘附分子(E-选择素、血管细胞粘附分子-1)[13、14]。
对骨髓移入尤其感兴趣的是趋化因子基质细胞来源的因子-1(SDF-1)和其受体CXCR4。用CXCR4抗体处理人祖细胞防止向人严重联合免疫缺陷(NOD/SCID)小鼠的移入。体外向CD34+CD38-/低细胞的SDF-1的CXCR-4依赖性迁移发现与体内移入和干细胞功能相关[10]。SDF-1α对CD34(+)细胞的活化导致牢固的粘附和跨内皮迁移,其依赖于LFA-1/ICAM-1(细胞内粘附分子-1)和VLA-4/VCAM-1(血管粘附分子-1)。此外,SDF-1诱导的CD34(+)/CXCR4(+)细胞通过内皮下细胞外基质的极化和外渗依赖于VLA-4和VLA-5[15]。
由于通过造血干细胞移植治疗多种重症的方法越来越多,非常需要更好地了解干细胞向骨髓归巢和移植宿主重聚集的机制,以获得具有更高成功率和长期移入的干细胞。
发明内容
根据本发明,药物在接受干细胞移植物的患者中促进了干细胞的归巢,其中所述药物包含受体的至少一种激动剂或其组合以及药学上可接受的载体,其中所述受体选自CCR3、CCR6或CCR8受体。
本发明的主题还有药剂用于制备提高干细胞归巢的药物方面的用途,其中所述药剂是受体的至少一种激动剂或其组合,其中所述受体选自CCR3、CCR6或CCR8受体。
在本发明用途的一个实施方案中,在移植之前用所述的激动剂处理祖细胞和干细胞。
在本发明的另一个实施方案中,所述的药剂用于移植造血祖细胞和干细胞、脐带血和胎盘干细胞和祖细胞、肝脏干细胞和祖细胞(卵形细胞)、间充质干细胞和祖细胞、内皮祖细胞、骨骼肌干细胞和祖细胞(卫星细胞)、平滑肌干细胞和祖细胞、肠干细胞和祖细胞、胚胎干细胞和遗传修饰的胚胎干细胞、成人胰岛/β干细胞和祖细胞、上皮祖细胞和干细胞、角膜、皮肤和毛囊的角化细胞干细胞、嗅(球)干细胞和祖细胞,以及来自各种成人组织的侧群细胞。
根据本发明药剂的用途增加造血干细胞对SDF-1诱导的细胞信号的敏感性。
具体地,根据本发明药剂用于治疗白血病、淋巴增殖性疾病、再生障碍性贫血、先天性骨髓疾病、实体瘤、自身免疫性疾病、炎症、原发性免疫缺陷、原发性系统性淀粉样变性病、系统性硬化症、心脏病、肝病、神经退行性病变、多发性硬化症、帕金森病、中风、脊髓损伤性糖尿病、骨病、皮肤病、皮肤、视网膜或角膜的替代疗法、其他先天性疾病、脉管疾病如动脉硬化症或心血管疾病。
在本发明的另一个实施方案中,所公开的促进造血干细胞成功归巢的方法包括:使造血干细胞在体内或离体与药剂接触,即与受体的至少一种激动剂或其组合接触,其中所述受体选自CCR3、CCR6或CCR8受体。
在本发明的另一个实施方案中,所公开的促进宿主患者中造血干细胞成功归巢的方法包括:在干细胞移植之前和/或过程中向接受干细胞移植的患者体内应用至少一种药剂,即选自CCR3、CCR6或CCR8受体的受体的激动剂或其组合。
在本发明方法中,宿主患者不加适应,或在亚致死、致死或超致死条件下进行适应。具体亚致死、致死或超致死条件包括用全身辐射处理,之后任选用重度骨髓抑制性或免疫抑制性药剂处理。亚致死、致死或超致死条件包括重度骨髓抑制性或免疫抑制性药剂处理,不进行全身辐射。表中示出了CCR3、CCR6和CCR8激动剂的典型例子。
表:与SDF-1α和CXCR4协同调控干细胞归巢的配基。
受体 | 配基 |
CCR3 | EotaxinEotaxin-2Eotaxin-3滤血CC趋化因子-1(HCC-1)滤血CC趋化因子-2(HCC-2)巨噬细胞炎症蛋白-1α(MIP-1α) |
活化调节的、正常T细胞表达并分泌的趋化因子(RANTES)单核细胞趋化蛋白-2(MCP-2)单核细胞趋化蛋白-3(MCP-3)单核细胞趋化蛋白-4(MCP-4)2-[(6-氨基-2-苯并噻唑基)硫代]-N-[1-[(3,4-二氯苯基)-甲基]-4-哌啶基]乙酰胺 | |
CCR6 | 巨噬细胞炎症蛋白-3α(MIP-3α) |
CCR8 | I309巨噬细胞炎症蛋白-1β(MIP-1β)LAG-1胸腺和活化受调控的趋化因子(TARC)病毒巨噬细胞炎症蛋白-I(vMIP-I) |
因此本研究涉及增加造血祖细胞和干细胞的敏感性的方法,以响应CXCR4活化而迁移,和/或增加与基质细胞的粘附能力。在该方面中,本发明提供了增加造血干细胞和祖细胞敏感性以用于临床移植的方法。该方法涉及在移植之前用CCR3、CCR6和CCR8激动剂预处理可移植的造血祖细胞和干细胞,和/或在干细胞移植之前、之中和/或之后对患者体内应用CCR3、CCR6和CCR8激动剂。
本发明的另一个方面涉及在患者中移植未成熟造血细胞的方法。患者需要在亚致死、致死或超致死条件下适应,例如通过全身辐射(TBI)和/或根据常规方案用重度骨髓抑制性或免疫抑制性药剂处理。例如,辐射的亚致死剂量为3-7Gy TBI,致死剂量为7-9.5Gy TBI,超致死剂量为9-16.5Gy TBI。重度骨髓抑制性药剂的例子有白消安、二甲基mileran和硫替派,免疫抑制性药剂的例子有强的松龙、甲基强的松龙、咪唑硫嘌呤、环磷酰胺、环磷酰胺等。
本发明的方法适于治疗可通过骨髓移植治愈的恶性疾病,如包括白血病、实体瘤癌症,先天性或遗传决定的造血异常,如包括腺苷脱氨酶(ADA)缺陷的严重联合免疫缺陷综合征(SCID),骨胳石化症、再生障碍性贫血、戈谢病、地中海贫血。
本发明还通过下面的非限制性实施方案来公开。
通过与CCR3、CCR6、CCR8激动剂体外预孵育调节归巢机制
例如,将来自人脐血、动员的外周血或骨髓的富含CD34+的祖细胞典型以100pM和10μM的浓度与一种CCR3、CCR6、CCR8激动剂孵育5分钟-12小时的时间。
下面示出了通过与CCR3、CCR6、CCR8激动剂预孵育调节归巢机制的原理。
预孵育后,将干细胞移植到用化疗方案或全身辐射预适应的患者体内。通过血小板和中性粒细胞计数监测造血系统的恢复。
可以如下文所述,通过与CCR3、CCR6、CCR8激动剂体内预孵育调节归巢机制。
在造血干细胞移植之前,通过全身辐射(TBI)和/或根据常规方案用接受用重度骨髓抑制性或免疫抑制性药剂处理,患者加以适应。在干细胞移植之前24h-0h,患者开始连续输注一种CCR3、CCR6、CCR8激动剂,使激动剂的血浆浓度达到100pM-10μM。通过化疗或辐射预适应之后24-48小时,患者接受来自人脐血、动员的外周血或骨髓的富含CD34+的祖细胞。这些细胞不经处理,或与浓度为100pM-10μM的一种CCR3、CCR6、CCR8激动剂处理5分钟-12小时的一段时间。通过血小板和中性粒细胞计数监测造血系统的恢复。
图:FDCP-Mix细胞进行体外趋化分析。在96孔趋化板(Neuroprobe,Cabin John,MD)中利用5-μm孔径的无聚乙烯吡咯烷酮的聚碳酸酯膜(Nucleopore,Neuroprobe)来分析趋化性。将400微升IMDM培养基加到孔底部,并添加有不同浓度的SDF-1α或MIP-3α(R&D Systems)。将含50.000FDCP-Mix细胞的100μl IMDM培养基加到趋化板的上部孔中。不添加或添加MIP-3α的100μl培养基加入到上部孔中。所有的分析都重复三次,迁移14小时后,在4个随机选择的视野中以63倍的放大倍数对迁移的细胞进行计数。
(A)通过增加趋化板底部孔中SDF-1α的浓度诱导了趋化迁移。
(B)MIP-3α以10-1000ng/ml培养基的浓度加入到底部孔中。MIP-3α不诱导FDCP-Mix祖细胞的趋化性迁移。
(C)SDF-1α以10ng/ml培养基的浓度加入到底部孔中。同时将FDCP-Mix祖细胞与10-1000ng/ml培养基浓度的MIP-3α共孵育。总之,MIP-3α增加FDCP-Mix向SDF-1α迁移的敏感性。对于CCR3受体激动剂Eotaxin、Eotaxin-2、Rantes、MCP-3、MCP-4和CCR8受体激动剂I-309也鉴定到了该效应。
参考文献
1.Lapidot T,P.F.,Doedens M,Murdoch B,Williams DE,Dick JE,Cytokine stimulation of multilineage hematopoiesis from immaturehuman cells engrafted in SCID mice.Sclence,1992.255:p.255.
2.Larochelle A,V.J.,Hanenberg H,Wang JC,Bhatia M,Lapidot T,MoritzT,Murdoch B,Xiao XL,Kato I,Williams DA,Dick JE,Identification ofprimitive human hematopoietic cells capable of repopulatingNOD/SCID mouse bone marrow:implications for gene therapy.NatMed,1996.2:p.1329-37.
3.Cashman J,B.K.,Hogge DE,Eaves AC,Eaves CJ,Sustainedproliferation,multi-lineage differentiation and maintenance ofprimitive human haemopoietic cells in NOD/SCID mice transplantedwith human cord blood.Br J Haematol,1997.98:p.1026-36.
4.Zanjanl ED,A.-P.G.,Livingston AG,Flake AW,Ogawa M,Human bonemarrow CD34- cells engraft in vivo and undergo multilineageexpression that includes giving rise to CD34+cells.Exp Hematol,1998.26:p.353-60.
5.Conneally E,C.J.,Petzer A,Eaves C,Expansion in vitro oftransplantable human cord blood stem cells demonstrated using aquantitative assay of their lympho-myeloid repopulating activity innonobese diabetic-scid/scid mice.Proc Natl Acad Sci USA,1997.94:p.9836-41.
6.Esmail D.Zanjani,A.W.F.,Graga Almeida-Porada,Nam Tran,andThalia Papayannopoulou,Homing of Human Cells in the Fetal SheepModel:Modulation by Antibodies Activating or Inhibiting Very LateActivation Antigen-4-Dependent Function.Blood,1999.94:p.2515-2522.
7.Greenberg AW,K.W.,Hammer DA,Relationship between selectin-mediated rolling of hematopoietic stem and progenitor cells andprogression in hematopoietic development.Blood,2000.95:p.478-86.
8.Mohle R,B.F.,Rafii S,Moore MA,Brugger W,Kanz L,Regulation oftransendothelial migration of hematopoietic progenitor cells.Ann N YAcad Sci,1999.872:p.176-85.
9.Naiyer AJ,J.D.,Ahn J,Mohle R,Peichev M,Lam G,Silverstein RL,Moore MA,Rafii S,Stromal derived factor-1-induced chemokinesis ofcord blood CD34(+)cells(long-term culture-initiating cells)throughendothelial cells is mediated by E-selectin.Blood,1999.94:p.4011-9.
10.Peled A,P.I.,Kollet O,Magid M,Ponomaryov T,Byk T,Nagler A,Ben-Hur H,Many A,Shultz L,Lider O,Alon R,Zipori D,Lapidot T,Dependence of human stem cell engraftment and repopulation ofNOD/SCID mice on CXCR4.Science,1999.283:p.845-8.
11.Aiuti A,W.I.,Bleul C,Springer T,Gutierrez-Ramos JC,The chemokineSDF-1 is a chemoattractant for human CD34+hematopoieticprogenitor cells and provides a new mechanism to explain themobilization of CD34+progenitors to peripheral blood.J Exp Med,1997.185:p.111-20.
12.Mohle R,B.F.,Rafii S,Moore MA,Brugger W,Kanz L,The chemokinereceptor CXCR-4 is expressed on CD34+hematopoietic progenitorsand leukemic cells and mediates transendothelial migration inducedby stromal cell-derived factor-1.Blood,1998.91:p.4523-30.
13.Schweitzer KM,D.A.,van der Valk P,Thijsen SF,Zevenbergen A,Theijsmeijer AP,van der Schoot CE,Langenhuijsen MM,Constitutiveexpression of E-selectin and vascular cell adhesion molecule-1 onendothelial cells of hematopoietic tissues.Am J Pathol,1996.148:p.165-75.
14.Jacobsen K,K.J.,Kincade PW,Osmond DG,Adhesion receptors onbone marrow stromal cells:in vivo expression of vascular celladhesion molecule-1by reticular celis and sinusoidal endothelium innormal and gamma-irradiated mice.Blood,1996.87:p.73-82.
15.Peled A,K.O.,Ponomaryov T,Petit I,Franitza S,Grabovsky V,SlavMM,Nagler A,Lider O,Alon R,Zipori D,Lapidot T,The chemokineSDF-1 activates the integrins LFA-1,VLA-4,and VLA-5 on immaturehuman CD34(+)cells:role in transendothelial/stromal migration andengraftment of NOD/SCID mice.Blood,2000.95:p.3289-96.
Claims (13)
1.一种药物,其包含受体的至少一种激动剂或其组合以及药学上可接受的载体,其中所述受体选自CCR3、CCR6或CCR8受体。
2.根据权利要求1的药物,其中所述的激动剂选自:CCR3受体激动剂:Eotaxin;Eotaxin-2;Eotaxin-3;滤血CC趋化因子-1(HCC-1);滤血CC趋化因子-2(HCC-2);巨噬细胞炎症蛋白-1α(MIP-1α);活化调节的、正常T细胞表达并分泌的趋化因子(RANTES);单核细胞趋化蛋白-2(MCP-2);单核细胞趋化蛋白-3(MCP-3);单核细胞趋化蛋白-4(MCP-4);2-[(6-氨基-2-苯并噻唑基)硫代]-N-[1-[(3,4-二氯苯基)-甲基]-4-哌啶基]乙酰胺;CCR6受体激动剂:巨噬细胞炎症蛋白-3α(MIP-3α);CCR8受体激动剂:I309;巨噬细胞炎症蛋白-1β(MIP-1β);LAG-1;胸腺和活化受调控的趋化因子(TARC);病毒巨噬细胞炎症蛋白-I(vMIP-I);以及保留其激动剂能力的其衍生物。
3.药剂用于制备促进干细胞归巢的药物中的用途,其中所述的药剂为受体的至少一种激动剂或其组合,其中所述受体选自CCR3、CCR6或CCR8受体。
4.根据前述权利要求的用途,其中所述的激动剂用于在移植之前处理祖细胞和干细胞。
5.根据前述权利要求一项或多项的用途,用于移植造血祖细胞和干细胞、脐带血和胎盘干细胞和祖细胞、肝脏干细胞和祖细胞(卵形细胞)、间充质干细胞和祖细胞、内皮祖细胞、骨骼肌干细胞和祖细胞(卫星细胞)、平滑肌干细胞和祖细胞、肠干细胞和祖细胞、胚胎干细胞和遗传修饰的胚胎干细胞、成人胰岛/β干细胞和祖细胞、上皮祖细胞和干细胞、角膜、皮肤和毛囊的角化细胞干细胞、嗅(球)干细胞和祖细胞,以及来自各种成人组织的侧群细胞。
6.根据前述权利要求一项或多项的用途,用于增加造血干细胞对SDF-1诱导的细胞信号的敏感性。
7.根据前述权利要求一项或多项的用途,用于治疗白血病、淋巴增殖性疾病、再生障碍性贫血、先天性骨髓疾病、实体瘤、自身免疫性疾病、炎症、原发性免疫缺陷、原发性系统性淀粉样变性病、系统性硬化症、心脏病、肝病、神经退行性病变、多发性硬化症、帕金森病、中风、脊髓损伤性糖尿病、骨病、皮肤病、皮肤、视网膜或角膜的替代疗法、其他先天性疾病、脉管疾病如动脉硬化症或心血管疾病。
8.促进造血干细胞成功归巢的方法,包括使造血干细胞在体内或离体与药剂接触,即与受体的至少一种激动剂或其组合接触,其中所述受体选自CCR3、CCR6或CCR8受体。
9.促进宿主患者中造血干细胞成功归巢的方法,包括在干细胞移植之前和/或过程中向接受干细胞移植的患者体内应用至少一种药剂,即选自CCR3、CCR6或CCR8受体的受体的激动剂或其组合。
10.前述权利要求的方法,其中所述的宿主患者不进行适应。
11.权利要求9的方法,其中所述的宿主患者在亚致死、致死或超致死条件下进行适应。
12.根据权利要求10或11的任意一项的方法,其中所述的亚致死、致死或超致死条件包括全身辐射处理,之后任选地用重度骨髓抑制性或免疫抑制性药剂处理。
13.根据权利要求10-12中任意一项的方法,其中所述的亚致死、致死或超致死条件包括重度骨髓抑制性或免疫抑制性药剂处理,不进行全身辐射。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03006552.8 | 2003-03-24 | ||
EP03006552 | 2003-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1764471A true CN1764471A (zh) | 2006-04-26 |
Family
ID=33040910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800079361A Pending CN1764471A (zh) | 2003-03-24 | 2004-03-24 | 趋化因子受体激动剂用于干细胞移植的用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070155663A1 (zh) |
EP (1) | EP1605966A1 (zh) |
JP (1) | JP2006521325A (zh) |
CN (1) | CN1764471A (zh) |
AU (1) | AU2004224755A1 (zh) |
CA (1) | CA2519920A1 (zh) |
MX (1) | MXPA05010140A (zh) |
WO (1) | WO2004084931A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106795497A (zh) * | 2014-08-12 | 2017-05-31 | 人类起源公司 | 被工程化以归巢至淋巴结b细胞区、皮肤或胃肠道的car‑t淋巴细胞 |
US10967005B2 (en) | 2013-03-15 | 2021-04-06 | Celgene Corporation | Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis |
US11130820B2 (en) | 2012-12-20 | 2021-09-28 | Celgene Corporation | Chimeric antigen receptors |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE551066T1 (de) * | 2004-06-21 | 2012-04-15 | Cleveland Clinic Foundation | Ccr-liganden für stammzellen-homing |
US9988611B2 (en) | 2011-12-01 | 2018-06-05 | Ap Biosciences, Inc. | Protein inhibitors to complement and VEGF pathways and methods of use thereof |
US20210123930A1 (en) * | 2019-10-10 | 2021-04-29 | Incyte Corporation | Biomarkers for graft-versus-host disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108514A1 (en) * | 1997-12-17 | 2003-06-12 | James Lillard | Chemokines as adjuvants |
CN1230538C (zh) * | 1998-07-10 | 2005-12-07 | 康纳克斯有限公司 | 与人ζ链胞外域特异性相互作用的免疫制剂 |
EP1149113A1 (en) * | 1999-02-03 | 2001-10-31 | Schering Corporation | Use of agonists or antagonists of mip-3a in therapy |
EP1185627A2 (en) * | 1999-06-01 | 2002-03-13 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
WO2001017558A2 (en) * | 1999-09-08 | 2001-03-15 | Schering Corporation | Novel uses of mammalian ccr6 receptors and related reagents |
US20030049696A1 (en) * | 2001-06-07 | 2003-03-13 | Norment Anne M. | Regulatory T cells and uses thereof |
-
2004
- 2004-03-24 US US10/550,593 patent/US20070155663A1/en not_active Abandoned
- 2004-03-24 JP JP2006504841A patent/JP2006521325A/ja not_active Abandoned
- 2004-03-24 CA CA002519920A patent/CA2519920A1/en not_active Abandoned
- 2004-03-24 MX MXPA05010140A patent/MXPA05010140A/es not_active Application Discontinuation
- 2004-03-24 CN CNA2004800079361A patent/CN1764471A/zh active Pending
- 2004-03-24 AU AU2004224755A patent/AU2004224755A1/en not_active Abandoned
- 2004-03-24 WO PCT/EP2004/003115 patent/WO2004084931A1/en active Application Filing
- 2004-03-24 EP EP04722854A patent/EP1605966A1/en not_active Withdrawn
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11130820B2 (en) | 2012-12-20 | 2021-09-28 | Celgene Corporation | Chimeric antigen receptors |
US10967005B2 (en) | 2013-03-15 | 2021-04-06 | Celgene Corporation | Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis |
US11806365B2 (en) | 2013-03-15 | 2023-11-07 | Celgene Corporation | Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis |
CN106795497A (zh) * | 2014-08-12 | 2017-05-31 | 人类起源公司 | 被工程化以归巢至淋巴结b细胞区、皮肤或胃肠道的car‑t淋巴细胞 |
Also Published As
Publication number | Publication date |
---|---|
EP1605966A1 (en) | 2005-12-21 |
WO2004084931A1 (en) | 2004-10-07 |
CA2519920A1 (en) | 2004-10-07 |
JP2006521325A (ja) | 2006-09-21 |
MXPA05010140A (es) | 2006-03-17 |
AU2004224755A1 (en) | 2004-10-07 |
US20070155663A1 (en) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
El Khoury et al. | Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications | |
Wright et al. | Hematopoietic stem cells are uniquely selective in their migratory response to chemokines | |
Barriga et al. | Hematopoietic stem cell transplantation: clinical use and perspectives | |
Sadeghi et al. | A study on the mechanisms involving the anti-inflammatory effect of amitriptyline in carrageenan-induced paw edema in rats | |
Lapidot et al. | The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice | |
CN103561788B (zh) | 干细胞的体内迁移诱导方法 | |
ES2418433T3 (es) | Modulación de receptores de catecolaminas | |
Kondo et al. | Induction of chemokine gene expression during allogeneic skin graft rejection1 | |
Fibbe et al. | Sustained engraftment of mice transplanted with IL-1-primed blood-derived stem cells. | |
EP1974012B1 (en) | Methods of improving stem cell homing and engraftment | |
Kawamura et al. | Xenotransplantation of bone marrow-derived human mesenchymal stem cell sheets attenuates left ventricular remodeling in a porcine ischemic cardiomyopathy model | |
WO2012159044A1 (en) | Stem cell mobilization and tissue repair and regeneration | |
Schroeder et al. | The role of chemokines in cutaneous allergic inflammation | |
CN1764471A (zh) | 趋化因子受体激动剂用于干细胞移植的用途 | |
Tian et al. | Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors | |
Muramatsu et al. | Detection of chimerism following vascularized bone allotransplantation by polymerase chain reaction using a Y‐chromosome specific primer | |
US20080279835A1 (en) | Method of Stem Cell Therapy for Cardiovascular Repair | |
Sobkow et al. | Prolonged transendothelial migration of human haematopoietic stem and progenitor cells (HSPCs) towards hydrogel-released SDF1 | |
WO2011019221A2 (en) | Agent for stimulating mobilization of endothelial progenitor cells | |
US20230142987A1 (en) | Modified macrophages, compositions and uses thereof | |
Stahl | A Study of Macrophages in the Aging Liver and in the Host Response to Engineered Lung Scaffolds | |
SK14372003A3 (sk) | Identifikácia parazitných plesní v organizme a ich liečenie | |
Sobkow et al. | Click here to download Manuscript: manuscript. doc Click here to view linked References | |
Koury et al. | Wintrobe’s clinical hematology | |
JP2017178875A (ja) | γδT細胞遊走促進剤およびそれを含む医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1087033 Country of ref document: HK |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20060426 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1087033 Country of ref document: HK |